Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia


Rochester, Minn., Jacksonville, Fla., Phoenix/Scottsdale, Ariz.

Trial status:

Open for Enrollment

Why is this study being done?

This open-label study is to determine the long-term safety and tolerability of momelotinib in previously enrolled study participants with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), post-essential thrombocythemia myelofibrosis (post-ET MF), polycythemia vera (PV), or essential thrombocythemia (ET), who have tolerated and achieved stable disease or better with momelotinib treatment while enrolled in a previous clinical trial.

Who is eligible to participate?

Inclusion Criteria: - Currently enrolled in study CCL0910E, YM387-II-02, or successfully completed - Able to comprehend and willing to sign informed consent form Exclusion Criteria: - Known hypersensitivity to momelotinib, its metabolites, or formulation excipients

Last updated:




IRB Number: